STOCK TITAN

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report first-quarter 2024 financial results on May 7, 2024, and host a conference call and webcast. The company focuses on rare immune system diseases, aiming to enhance patient lives.

Loading...
Loading translation...
Argus Session date unavailable
+2.75% session move Open Argus
Details

News Market Reaction – XFOR

The recorded move for XFOR in the trading session of this news was +2.75%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024.

The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13745487. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay will be available on the website.

About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com

Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will X4 Pharmaceuticals report its first-quarter 2024 financial results?

X4 Pharmaceuticals will report its first-quarter 2024 financial results on May 7, 2024.

What is the conference call and webcast schedule for X4 Pharmaceuticals?

X4 Pharmaceuticals will host a conference call and webcast on May 7, 2024, at 8:30 a.m. ET.

How can I access the conference call and webcast for X4 Pharmaceuticals?

The conference call can be accessed by dialing 1-877-451-6152 (US) or 1-201-389-0879 (international) with the conference ID: 13745487. The webcast will be available on X4 Pharmaceuticals' investor relations website at www.x4pharma.com.

Keep reading